Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation

Overview

Journal Sci Rep

Specialty Science

Date 2016 Apr 28

PMID 27117228

Citations 6

Authors

Yu-Tung Li

Tomoyuki Nishikawa

Yasufumi Kaneda

Affiliations

Soon will be listed here.

Abstract

Tumours constitute unique microenvironments where various blood cells and factors are exposed as a result of leaky vasculature. In the present study, we report that thrombin enrichment in B16F10 melanoma led to platelet aggregation, and this property was exploited to administer an anticancer cytokine, interferon-gamma induced protein 10 (IP10), through the formation of a platelet-IP10 complex. When intravenously infused, the complex reached platelet microaggregates in the tumour. The responses induced by the complex were solely immune-mediated, and tumour cytotoxicity was not observed. The complex suppressed the growth of mouse melanoma in vivo, while both platelets and the complex suppressed the accumulation of FoxP3(+) regulatory T cells in the tumour. These results demonstrated that thrombin-dependent platelet aggregation in B16F10 tumours defines platelets as a vector to deliver anticancer cytokines and provide specific treatment benefits.

Citing Articles

Proteomics reveals differentially regulated pathways when comparing grade 2 and 4 astrocytomas.

Verissimo D, C Camillo-Andrade A, D M Santos M, Sprengel S, Zanine S, Borba L PLoS One. 2023; 18(11):e0290087.

PMID: 37967105 PMC: 10651032. DOI: 10.1371/journal.pone.0290087.

Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects.

Dai Z, Zhao T, Song N, Pan K, Yang Y, Zhu X Front Pharmacol. 2022; 13:1026386.

PMID: 36330089 PMC: 9623298. DOI: 10.3389/fphar.2022.1026386.

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.

Zhang M, Liu K, Wang M RSC Adv. 2022; 9(58):33903-33911.

PMID: 35528929 PMC: 9073714. DOI: 10.1039/c9ra04590b.

Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies.

Yu L, Guo Y, Chang Z, Zhang D, Zhang S, Pei H Front Oncol. 2021; 11:764119.

PMID: 34722319 PMC: 8551800. DOI: 10.3389/fonc.2021.764119.

Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis.

Plantureux L, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L Cancers (Basel). 2018; 10(11).

PMID: 30441823 PMC: 6266827. DOI: 10.3390/cancers10110441.

References

Qi C, Wei B, Ye J, Yang Y, Li B, Zhang Q . P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. PLoS One. 2014; 9(3):e91320. PMC: 3954694. DOI: 10.1371/journal.pone.0091320. View

Holash J, Wiegand S, Yancopoulos G . New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999; 18(38):5356-62. DOI: 10.1038/sj.onc.1203035. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Wu A, Senter P . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23(9):1137-46. DOI: 10.1038/nbt1141. View

Kumar A, Mhaskar R, Grossman B, Kaufman R, Tobian A, Kleinman S . Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 2014; 55(5):1116-27. DOI: 10.1111/trf.12943. View

Elyamany G, Alzahrani A, Bukhary E . Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014; 8:129-37. PMC: 4259501. DOI: 10.4137/CMO.S18991. View

Struyf S, Burdick M, Proost P, Van Damme J, Strieter R . Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res. 2004; 95(9):855-7. DOI: 10.1161/01.RES.0000146674.38319.07. View

Vogel I, Verbinnen B, Maes W, Boon L, Van Gool S, Ceuppens J . Foxp3+ regulatory T cells are activated in spite of B7-CD28 and CD40-CD40L blockade. Eur J Immunol. 2013; 43(4):1013-23. DOI: 10.1002/eji.201242737. View

Ahmad R, Menezes J, Knafo L, Ahmad A . Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells. J Leukoc Biol. 2001; 69(1):123-8. View

10.

Liebman H . Thrombocytopenia in cancer patients. Thromb Res. 2014; 133 Suppl 2:S63-9. DOI: 10.1016/S0049-3848(14)50011-4. View

11.

Kirszberg C, Rumjanek V, Monteiro R . Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. Thromb Res. 2004; 115(1-2):123-9. DOI: 10.1016/j.thromres.2004.08.001. View

12.

Nishikawa T, Tung L, Kaneda Y . Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in mice. Mol Ther. 2014; 22(12):2046-2055. PMC: 4429689. DOI: 10.1038/mt.2014.128. View

13.

Mitchell B, Mahalingam M . The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma. Histol Histopathol. 2014; 29(12):1539-46. DOI: 10.14670/HH-29.1539. View

14.

Dvorak H . Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol. 2003; 162(6):1747-57. PMC: 1868128. DOI: 10.1016/s0002-9440(10)64309-x. View

15.

Nierodzik M, Karpatkin S . Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10(5):355-62. DOI: 10.1016/j.ccr.2006.10.002. View

16.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

17.

June C . Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007; 117(6):1466-76. PMC: 1878537. DOI: 10.1172/JCI32446. View

18.

Farnsworth R, Lackmann M, Achen M, Stacker S . Vascular remodeling in cancer. Oncogene. 2013; 33(27):3496-505. DOI: 10.1038/onc.2013.304. View

19.

VanDeWater L, Tracy P, Aronson D, Mann K, Dvorak H . Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res. 1985; 45(11 Pt 1):5521-5. View

20.

Asanuma K, Wakabayashi H, Okamoto T, Asanuma Y, Akita N, Yoshikawa T . The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone. Breast Cancer. 2012; 20(3):241-6. DOI: 10.1007/s12282-012-0334-5. View